Cargando…

Emerging Immunotherapy Approaches for Treating Prostate Cancer

Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Lingbin, Yang, Yuanquan, Mortazavi, Amir, Zhang, Jingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531627/ https://www.ncbi.nlm.nih.gov/pubmed/37762648 http://dx.doi.org/10.3390/ijms241814347

Ejemplares similares

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields
por: Liu, Shiyu, et al.
Publicado: (2021)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Immunotherapy in Prostate Cancer
por: Fay, Emily K., et al.
Publicado: (2020)

A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer
por: Puig-Saenz, Carles, et al.
Publicado: (2023)

Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
por: Rahman, Md. Mominur, et al.
Publicado: (2022)

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
por: Wang, Bin, et al.
Publicado: (2021)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
por: Sridaran, Dhivya, et al.
Publicado: (2023)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Emerging Targets of Immunotherapy in Gynecologic Cancer
por: Cheng, Hongyan, et al.
Publicado: (2020)

Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

A Perspective of Immunotherapy for Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2016)

Is There a Role for Immunotherapy in Prostate Cancer?
por: Rizzo, Alessandro, et al.
Publicado: (2020)

The Cellular and Molecular Immunotherapy in Prostate Cancer
por: Mukherjee, Anirban Goutam, et al.
Publicado: (2022)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
por: Zhang, Jingsong
Publicado: (2014)

Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
por: Slovin, Susan F
Publicado: (2013)

Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
por: Mukaida, Naofumi, et al.
Publicado: (2018)

Emerging Trends in Immunotherapy for Cancer
por: Mishra, Alok K., et al.
Publicado: (2022)

Focal Therapy in the Management of Prostate Cancer: An Emerging Approach for Localized Prostate Cancer
por: Nomura, Takeo, et al.
Publicado: (2012)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer
por: Xu, Pengfei, et al.
Publicado: (2022)

Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
por: Ionescu, Filip, et al.
Publicado: (2022)

Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Editorial: Emerging engineering approaches in cancer immunotherapy
por: Xu, Jialu, et al.
Publicado: (2022)

Emerging Nano‐/Microapproaches for Cancer Immunotherapy
por: Mi, Yu, et al.
Publicado: (2019)

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
por: Johnson, Kai, et al.
Publicado: (2021)

Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy
por: Yang, Yunrong, et al.
Publicado: (2022)

Immunotherapy approaches for hematological cancers
por: Lanier, Olivia L., et al.
Publicado: (2022)

Dendritic Cell-Based Immunotherapy for Prostate Cancer
por: Jähnisch, Hanka, et al.
Publicado: (2010)

From Bench to Bedside: Immunotherapy for Prostate Cancer
por: Tse, Brian Wan-Chi, et al.
Publicado: (2014)

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2015)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Immunotherapy for Prostate Cancer Enters Its Golden Age
por: Boikos, Sosipatros A., et al.
Publicado: (2012)

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
por: Kiessling, Andrea, et al.
Publicado: (2012)

Immunotherapy in prostate cancer: current state and future perspectives
por: Handa, Shivani, et al.
Publicado: (2020)

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0hteghbujohdo8657v0rnhnto